GLP-1 Eligibility: Do You Qualify?

Adult weight-management medication is commonly considered at BMI 30 or higher, or BMI 27 or higher with a weight-related condition. That is a starting point for assessment, not automatic qualification. A licensed clinician must evaluate the exact product, indication, history and risks. NIDDK: prescription weight-management medicines

REMEVi provides care in English and Spanish in 49 states and Washington, DC, excluding Louisiana. Clinician-required GLP-1 labs are included; the clinician decides the tests and timing. Geographic availability does not guarantee a prescription.

Which eligibility question are you asking?

Treatment purpose	Starting point for discussion	What not to assume
Adult weight management	BMI and a weight-related condition when applicable, followed by clinical assessment	BMI alone guarantees treatment
Type 2 diabetes	A diabetes diagnosis and glucose-management needs under the exact label	The weight-management BMI threshold applies to every diabetes prescription
Cardiovascular, kidney, liver or sleep-apnea treatment	The named product’s indication and the required disease characteristics	Every GLP-1 carries the same additional approvals
Adolescent treatment	A pediatric approval, age and product-specific criteria	Adult BMI cutoffs or adult doses can be transferred to children
Compounded preparation	An individualized medical need and lawful prescribing/compounding assessment	A branded approval automatically covers it

For example, Wegovy injection includes certain adolescent and MASH indications that Wegovy tablets do not. Zepbound’s sleep-apnea indication is for adults with obesity and moderate-to-severe obstructive sleep apnea. Ozempic injection’s kidney indication requires type 2 diabetes and chronic kidney disease. Wegovy label, Zepbound label, Ozempic injection label

These examples explain FDA-approved products; they do not establish that REMEVi treats every listed age group or condition. See injection names and approved uses.

Weight-related conditions and BMI

Conditions such as high blood pressure or type 2 diabetes can be relevant to the overweight-plus-condition pathway. Your clinician must establish the diagnosis and whether it meets the chosen product’s criteria. BMI is calculated from height and weight; it does not capture the full clinical picture or replace a medical history.

Bring accurate recent measurements and existing diagnoses. Do not change or round measurements to reach a cutoff. If the first assessment does not support treatment, the next step may be further evaluation or a different care plan.

Contraindications are different from precautions

Semaglutide and tirzepatide labels list personal or family medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN2), and serious hypersensitivity to the product as contraindications. The thyroid warning concerns a specific cancer history, not every thyroid diagnosis. Wegovy, section 4, Zepbound, section 4

Previous pancreatitis, gallbladder disease, kidney problems, diabetic retinopathy or severe digestive symptoms need assessment. They should not all be presented as the same formal contraindication. Severe gastroparesis is a situation in which these labels do not recommend use. Taking insulin or sulfonylureas can increase low-glucose risk and may require changes directed by the clinician.

Tell the team about pregnancy, plans to become pregnant, breastfeeding and upcoming anesthesia or deep sedation. Weight-loss treatment is not used during pregnancy. For weight reduction, Wegovy’s label directs stopping at least two months before a planned pregnancy; tirzepatide has separate contraception instructions. Follow the exact prescriber’s plan. Wegovy safety and pregnancy sections, Zepbound safety and reproductive sections

What the consultation and labs review

Have the following ready:

• Current medicines, supplements, doses and allergies.
• Diagnoses, relevant family history and prior GLP-1 treatment.
• Recent height and weight, prior lab reports with dates, and current symptoms.
• Pregnancy plans and any planned procedure requiring anesthesia.
• The treatment goal and practical questions about cost and follow-up.

There is no universal “GLP-1 lab panel” to order yourself. Tests should answer a clinical question. REMEVi includes clinician-required GLP-1 labs, without implying a fixed panel, quarterly schedule or coverage for every unrelated outside test. Read what GLP-1 lab tests may check.

For terminology during a bilingual appointment, use the English–Spanish GLP-1 glossary.

If you are not eligible

The clinician may recommend another treatment, additional testing or follow-up without medication. An insurance approval and a clinical prescription are separate decisions; neither should be inferred from completing an online form.

Compounded preparations are not FDA-approved and are not an automatic alternative when a branded product is inappropriate. They do not remove the need to evaluate the molecule’s risks or establish a patient-specific medical need. FDA: compounded-drug risks

See if you qualify for a clinical review, or explore semaglutide care options.

Educational information, not a diagnosis or promise of treatment.